NCT04917302View on ClinicalTrials.gov

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Schizophrenia
Interventions
DRUG

NMDAE plus AIFA

Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.

DRUG

NMDAE plus Placebo Cap

Use of an NMDA enhancer plus placebo as a comparator

Trial Locations (1)

Unknown

RECRUITING

Department of Psychiatry, China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

China Medical University Hospital

OTHER